Sondel Paul M, Hank Jacquelyn A, Gan Jacek, Neal Zane, Albertini Mark R
Department of Pediatrics, Human Oncology, Genetics & Medicine and the University of Wisconsin Comprehensive Cancer Center, The University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI 53792, USA.
Curr Opin Investig Drugs. 2003 Jun;4(6):696-700.
Advances in preclinical and clinical development have demonstrated that monoclonal antibodies and immuno-activating cytokines have a beneficial role in certain clinical oncology settings. Genetic engineering has now been used to create 'immunocytokines (ICs)'. These are fusion proteins that consist of an immune-activating cytokine linked to a tumor-reactive monoclonal antibody. Preclinical data demonstrate that ICs are far more effective in murine tumor models than the separate molecules from which they are derived. Clinical testing of ICs has recently begun using an anti-GD2 monoclonal antibody linked to interleukin-2 (IL-2) (hu14.18-IL-2), and using an antibody directed against the human epithelial cell adhesion molecule linked to IL-2 (KS-IL-2).
临床前和临床开发的进展表明，单克隆抗体和免疫激活细胞因子在某些临床肿瘤学环境中具有有益作用。基因工程现已用于制造“免疫细胞因子（ICs）”。这些是融合蛋白，由与肿瘤反应性单克隆抗体相连的免疫激活细胞因子组成。临床前数据表明，ICs在小鼠肿瘤模型中比其衍生的单独分子更有效。ICs的临床试验最近已开始，使用与白细胞介素-2（IL-2）相连的抗GD2单克隆抗体（hu14.18-IL-2），以及使用与IL-2相连的针对人上皮细胞粘附分子的抗体（KS-IL-2）。
